drugset / Trial / NCT07626034
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
Phase 1/2
Not yet recruiting
9 enrolled
Shanghai Zhongze Therapeutics Co., Ltd.
Yale University · collab
Non-randomizedSequentialOpen-labelBasic science
Summary
This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
Timeline
- Start
- 2026-08
- Primary completion
- 2027-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIPI6398 | Unknown | 1 mg | Oral |
| Subject | SIPI6398 | Unknown | 3 mg | Oral |
| Subject | SIPI6398 | Unknown | 6 mg | Oral |
| Subject | SIPI6398 | Unknown | 12 mg | Oral |
| Subject | SIPI6398 | Unknown | 18 mg | Oral |